Abstract:In the field of medicine, groundbreaking changes occur when compelling evidence on novel treatments, diagnostic procedures, or theories shatters a longstanding tradition embraced as an unwavering mantra. In the realm of antithrombotic treatments, direct oral anticoagulants (DOACs) represented a Copernican revolution in the last decade, disrupting the 50-year dominance of warfarin. In fact, warfarin, with its numerous pharmacological and food interactions and the mandatory need for regular laboratory monitoring, is unlikely to pass even phase 1 of the current extensive clinical drug development process. Nevertheless, it represents an institution in the treatment of atrial fibrillation (AF). In the last 10 years, DOACs have played a triple task: (i) providing a viable alternative and later a preferred choice over warfarin, (ii) challenging the mental taboo of requiring regular laboratory testing to guarantee the constant effectiveness of anticoagulation, and (iii) surpassing the prescriptive constraints set up by regulatory authorities. The RE-LY trial on dabigatran in 2009 started a new era of stroke prevention in patients with AF. In the early 2010s, owing to other positive large randomized trials of rivaroxaban, apixaban, and edoxaban, European guidelines stipulated to consider DOACs (2012) and then prefer them (2016) over vitamin K antagonists (VKAs) in the thromboembolic prophylaxis of patients with AF ( Figure 1 ). 1

Ten years of direct oral anticoagulants: lessons learned and challenges ahead